Glenmark to commercialise BeiGene's oncology medicines Tislelizumab and Zanubrutinib in India
Singapore, May 21 -- Glenmark will be responsible for locally required development, registration and distribution of BeiGene's innovative oncology medicines.
Glenmark Specialty S.A., a subsidiary of Indian firm Glenmark Pharmaceuticals has announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will register and commercialise BeiGene's oncology medicines, Tislelizumab and Zanubrutinib in India.
Speaking on this partnership, Alok Malik, President and Business Head - India Formulations, Glenmark Pharmaceuticals said, "The addition of Tislelizumab and Zanubrutinib to our oncology portfolio underscores our dedication to the cancer patients' community and our commitm...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.